ESLA (Estrella Immunopharma) Ending Cash Position: $0.15 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESLA Estrella Immunopharma Inc ESLA
12 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Estrella Immunopharma Ending Cash Position?

Estrella Immunopharma ESLA -1.11% 12 Ending Cash Position is $0.15 Mil as of Jun. 2026. GuruFocus rates ESLA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Estrella Immunopharma's Ending Cash Position for the quarter that ended in Jun. 2026 was $0.15 Mil.

Estrella Immunopharma's quarterly Ending Cash Position increased from Dec. 2025 ($1.38 Mil) to Mar. 2026 ($1.93 Mil) but then declined from Mar. 2026 ($1.93 Mil) to Jun. 2026 ($0.15 Mil).

Estrella Immunopharma's annual Ending Cash Position increased from Jun. 2023 ($2.48 Mil) to Jun. 2024 ($4.17 Mil) but then declined from Jun. 2024 ($4.17 Mil) to Dec. 2025 ($1.38 Mil).

Estrella Immunopharma Ending Cash Position Related Terms

Estrella Immunopharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Estrella Immunopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Estrella Immunopharma Ending Cash Position Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Dec25
Ending Cash Position
0.00 4.09 2.48 4.17 1.38

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.63 1.38 1.93 0.15
ESLA
12GF Score
Estrella Immunopharma Inc ESLA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Estrella Immunopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Estrella Immunopharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.917+0.467
=1.38

Estrella Immunopharma's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.928+-1.781
=0.15

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.15 Mil mean?
Estrella Immunopharma (ESLA) has a Ending Cash Position of $0.15 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Estrella Immunopharma and its competitors.
Is Estrella Immunopharma's Ending Cash Position too high?
Estrella Immunopharma's current Ending Cash Position is $0.15 Mil. Overall, Estrella Immunopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Estrella Immunopharma's Ending Cash Position compare to LITS and NNVC?
Estrella Immunopharma's Ending Cash Position of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Estrella Immunopharma and its competitors. Estrella Immunopharma's current Ending Cash Position is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Estrella Immunopharma stock overvalued right now?
Estrella Immunopharma (ESLA) has a current Ending Cash Position of $0.15 Mil. The current Ending Cash Position is $0.15 Mil. Estrella Immunopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Estrella Immunopharma (ESLA), the current Ending Cash Position is $0.15 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Estrella Immunopharma Business Description

Address 5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
12GF Score

Get the complete analysis for ESLA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price